Surgery and OncologySurgery and OncologyХирургия и онкология2949-5857Publishing House ABV Press87610.17650/2949-5857-2026-16-1-50-55ORIGINAL REPORTОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕResearch ArticleReal-world 5-year overall survival in patients with metastatic non-small cell lung cancer and high PD-L1 expression treated by mono-immunotherapyПятилетняя общая выживаемость у пациентов с метастатическим немелкоклеточным раком легкого и высоким уровнем экспрессии PD-L1, получающих моноиммунотерапиюhttps://orcid.org/0000-0002-0620-2696YudinDenis I.ЮдинДенис Иванович
Russian Federation
yudinden@mail.ruhttps://orcid.org/0000-0003-4469-502XLaktionovK. K.ЛактионовК. К.
Russian Federation
yudinden@mail.ruhttps://orcid.org/0000-0002-6244-4294BrederV. V.БредерВ. В.
Russian Federation
yudinden@mail.ruN.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaФГБУ «Национальный медицинский исследовательский центр онкологии им. Н. Н. Блохина» Минздрава РоссииN.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaФГАОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России15032026161505512122025Copyright ©; 2026, ABV-pressCopyright ©; 2026, АБВ-пресс2026ABV-pressАБВ-прессhttps://onco-surgery.info/jour/about/editorialPolicieshttps://onco-surgery.info/jour/article/view/876

Background. The efficacy of immunotherapy in patients with metastatic non-small cell lung cancer correlates with PD-L1 expression in clinical trials.

Aim. To evaluate real-world overall survival (OS) in patients with PD-L1 expression scores 50–89 % and 90–100 % who received immunotherapy as the 1st line treatment.

Materials and methods. This real-world single-site retrospective study included patients with metastatic non-small cell lung cancer without driving EGFR / ALK mutations and high PD-L1 expression score (50–100 %) who received anti-PD-1 / PD-L1 mono-immunotherapy at the N. N. Blokhin National Research Medical Center of Oncology (2015–2022). Primary endpoint was OS.

Results. The study included 28 patients. Median follow-up duration was 66.15 months. Median OS for patients with PD-L1 expression 50–89 % was 34.4 months (95 % confidence interval 24.3–44.4). The 5-year OS for patients with PD-L1 expression 90–100 % was 70.1 % versus 17.6 % in patients with PD-L1 expression 50–89 % (hazard ratio 0.26 (95 % confidence interval 0.07–0.9)).

Conclusion. PD-L1 expression score 90–100 % was associated with better five-year outcomes for mono-immunotherapy in 1st line treatment.

Введение. Эффективность лечения ингибиторами иммунных контрольных точек пациентов с метастатическим немелкоклеточным раком легкого коррелирует с ростом экспрессии PD-L1 в клинических исследованиях.

Цель исследования – оценить 5-летнюю общую выживаемость (ОВ) пациентов с метастатическим немелкоклеточным раком легкого и уровнем экспрессии PD-L1 50–89 и 90–100 %, получающих иммунотерапию в 1-й линии лечения, в реальной клинической практике.

Материалы и методы. В данное одноцентровое ретроспективное исследование включали пациентов без активирующих мутаций в генах EGFR / ALK с высокой экспрессией PD-L1 (50–100 %), получавших иммунотерапию анти-PD-1 / PD-L1 ингибиторами в Национальном медицинском исследовательском центре онкологии им. Н. Н. Блохина в период 2015–2022 гг. Первичной конечной точкой служила ОВ.

Результаты. В исследование включены 28 пациентов. Медиана времени наблюдения составила 66,15 мес. Медиана ОВ у пациентов с экспрессией PD-L1 50–89 % достигла 34,4 мес (95 % доверительный интервал 24,3–44,4). Пятилетняя ОВ пациентов с экспрессией PD-L1 90–100 и 50–89 % составила 70,1 % против 17,6 % соответственно (отношение рисков 0,26; 95 % доверительный интервал 0,07–0,9).

Заключение. Уровень экспрессии PD-L1 90–100 % ассоциируется с лучшими результатами 5-летней ОВ на фоне моноиммунотерапии в 1-й линии лечения.

non-small cell lung canceroverall survivalimmunotherapylong-term outcomeshigh PD-L1 expressionнемелкоклеточный рак легкогообщая выживаемостьиммунотерапияотдаленный результатвысокая экспрессия PD-L1Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677–704. DOI: 10.1146/annurev.immunol.26.021607.090331Gettinger S., Horn L., Jackman D. et al. Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: results from the CA209-003 study. J Clin Oncol 2018;36(17):1675–84. DOI: 10.1200/JCO.2017.77.0412Borghaei H., Gettinger S., Vokes E.E. et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol 2021;39(7):723–33. DOI: 10.1200/JCO.20.01605. Erratum in: J Clin Oncol 2021;39(10):1190. DOI: 10.1200/JCO.21.00546Herbst R.S., Garon E.B., Kim D.W. et al. Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC. J Thorac Oncol 2021;16(10):1718–32. DOI: 10.1016/j.jtho.2021.05.001Mazieres J., Rittmeyer A., Gadgeel S. et al. Atezolizumab versus docetaxel in pretreated patients with NSCLC: final results from the randomized phase 2 POPLAR and phase 3 OAK clinical trials. J Thorac Oncol 2021;16(1):140–50. DOI: 10.1016/j.jtho.2020.09.022Reck M., Rodríguez-Abreu D., Robinson A.G. et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥50. J Clin Oncol 2021;39(21):2339–49. DOI: 10.1200/JCO.21.00174Garon E.B., Hellmann M.D., Rizvi N.A. et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 2019;37(28):2518–27. DOI: 10.1200/JCO.19.00934De Castro G. Jr, Kudaba I., Wu Y.L. et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score ≥1 % in the KEYNOTE-042 study. J Clin Oncol 2023;41(11):1986–91. DOI: 10.1200/JCO.21.02885Rizvi N.A., Cho B.C., Reinmuth N. et al.; MYSTIC Investigators. durvalumab with or without tremelimumab versus standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol 2020;6(5):661–74. DOI: 10.1001/jamaoncol.2020.0237. Erratum in: JAMA Oncol 2020;6(11):1815. DOI: 10.1001/jamaoncol.2020.5538Carbone D.P., Reck M., Paz-Ares L. et al.; CheckMate 026 Investigators. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med 2017;376(25):2415–26. DOI: 10.1056/NEJMoa1613493Herbst R.S., Giaccone G., de Marinis F. et al. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC. N Engl J Med 2020;383(14):1328–39. DOI: 10.1056/NEJMoa1917346Morita M., Tamiya M., Fujimoto D. et al. Prediction of patients with a tumor proportion score >50 % who do not respond to first-line monotherapy with pembrolizumab. BMC Cancer 2020;20(1):93. DOI: 10.1186/s12885-020-6582-4Shah M., Hubbard R.A., Mamtani R. et al. Very high PD-L1 expression as a prognostic indicator of overall survival among patients with advanced non-small cell lung cancer receiving anti-PD-(L)1 monotherapies in routine practice. Pharmacoepidemiol Drug Saf 2022;31(10):1121–6. DOI: 10.1002/pds.5487Jackson A., Chang N., Akurang D. et al. Real-world immunotherapy use and effectiveness in advanced NSCLC with programmed death-ligand 1 greater than or equal to 50 % and greater than or equal to 90. JTO Clin Res Rep 2023;4(12):100601. DOI: 10.1016/j.jtocrr.2023.100601Ricciuti B., Elkrief A., Lin J. et al. Three-year overall survival outcomes and correlative analyses in patients with NSCLC and high (50–89 %) versus very high (≥90 %) programmed death-ligand 1 expression treated with first-line pembrolizumab or cemiplimab. JTO Clin Res Rep 2024;5(9):100675. DOI: 10.1016/j.jtocrr.2024.100675